Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
759 studies found for:    Epoetin alfa OR Epogen, Procrit[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Completed HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Condition: Chronic Kidney Disease
Intervention: Drug: HX575 epoetin alfa (Sandoz)
2 Withdrawn Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
Condition: Anemia
Intervention: Drug: Epoetin Alfa plus Iron
3 Completed Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Conditions: Anemia;   Chronic Kidney Disease (CKD)
Interventions: Drug: HX575 epoetin alfa;   Drug: US-licensed epoetin alfa
4 Terminated
Has Results
Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
Condition: Subarachnoid Hemorrhage
Interventions: Drug: Epoetin alfa;   Drug: Saline
5 Completed Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia
Condition: Friedreich's Ataxia
Intervention: Drug: Epoetin alfa
6 Terminated
Has Results
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
Condition: Anemia
Interventions: Drug: Peginesatide;   Drug: Epoetin alfa
7 Completed
Has Results
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Conditions: Renal Failure , Chronic;   Anemia
Interventions: Drug: Epoetin Alfa;   Other: Standard of care
8 Withdrawn Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia
Condition: Anemia
Intervention: Drug: Epoetin alfa
9 Unknown  PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects
Condition: Healthy
Intervention: Drug: Epoetin Alfa
10 Unknown  PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
Condition: Healthy
Intervention: Drug: Epoetin Alfa
11 Completed Efficacy Study of Epoetin Alfa in Friedreich Ataxia
Condition: Friedreich Ataxia
Interventions: Drug: Epoetin alfa;   Drug: Placebo
12 Unknown  PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
Condition: Healthy
Intervention: Drug: Epoetin Alfa
13 Unknown  PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects
Condition: Healthy
Intervention: Drug: Epoetin Alfa
14 Completed
Has Results
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
Condition: Anemia
Interventions: Drug: Epoetin alfa 3 times weekly /once weekly;   Drug: Epoetin alfa once weekly;   Drug: Epoetin alfa once every two weeks
15 Completed
Has Results
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
Conditions: Anemia;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: epoetin alfa
16 Terminated
Has Results
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
Condition: Hemostasis, Surgical
Interventions: Drug: Epoetin alfa;   Drug: Standard of Care
17 Terminated A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
Conditions: Gastrointestinal Cancer;   Rectal Cancer
Intervention: Drug: Procrit (epoetin alfa)
18 Terminated Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Condition: Anemia
Intervention: Drug: Epoetin Alfa
19 Withdrawn Epoetin Alfa for HIV-Associated Neuropathy Trial
Conditions: HIV Infections;   Neuropathy
Intervention: Drug: epoetin alfa
20 Completed An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
Conditions: Anemia;   HIV Infections
Intervention: Drug: Epoetin alfa

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.